Treatment with EGCG inhibited the elevation of IL-6 (HE group: 0.45 ± 0.32 ng/g tissue, p = 0.03 vs. MD; LE group: 0.41 ± 0.15 ng/g tissue, p = 0.03 vs. MD, Figure 6A), MCP-1 (HE group: 1.83 ± 0.89 ng/g tissue, p = 0.01 vs. MD; LE group: 1.87 ± 1.17 ng/g tissue, p = 0.01 vs. MD, Figure 6B), and TNF-alpha (HE group: 8.87 ± 4.24 ng/g tissue, p < 0.001 vs. MD; LE group: 10 ± 3.76 ng/g tissue, p < 0.001 vs. MD, Figure 6C) in both low- and high-dose EGCG groups. The gene discussed is CCL2; the disease is Menkes disease.